Aligned Genetics, Inc.

KOSDAQ:A238120 Stock Report

Market Cap: ₩55.7b

Aligned Genetics Past Earnings Performance

Past criteria checks 1/6

Aligned Genetics has been growing earnings at an average annual rate of 2.4%, while the Life Sciences industry saw earnings declining at 1.8% annually. Revenues have been growing at an average rate of 11.8% per year. Aligned Genetics's return on equity is 7.8%, and it has net margins of 18.2%.

Key information

2.40%

Earnings growth rate

-1.93%

EPS growth rate

Life Sciences Industry Growth53.72%
Revenue growth rate11.83%
Return on equity7.83%
Net Margin18.18%
Last Earnings Update31 Dec 2025

Recent past performance updates

Analysis Article • Apr 01

Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak Profit

The market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...

Recent updates

Analysis Article • Apr 01

Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak Profit

The market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...
Analysis Article • Feb 05

Aligned Genetics, Inc.'s (KOSDAQ:238120) Share Price Could Signal Some Risk

With a median price-to-earnings (or "P/E") ratio of close to 15x in Korea, you could be forgiven for feeling...
Analysis Article • Nov 12

These 4 Measures Indicate That Aligned Genetics (KOSDAQ:238120) Is Using Debt Safely

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 20

Aligned Genetics, Inc.'s (KOSDAQ:238120) Shareholders Might Be Looking For Exit

With a price-to-earnings (or "P/E") ratio of 16x Aligned Genetics, Inc. ( KOSDAQ:238120 ) may be sending bearish...
Analysis Article • Aug 12

Aligned Genetics, Inc.'s (KOSDAQ:238120) Business Is Yet to Catch Up With Its Share Price

Aligned Genetics, Inc.'s ( KOSDAQ:238120 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell...
Analysis Article • Apr 06

If You Like EPS Growth Then Check Out Aligned Genetics (KOSDAQ:238120) Before It's Too Late

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Feb 11

Update: Aligned Genetics (KOSDAQ:238120) Stock Gained 29% In The Last Three Years

While Aligned Genetics, Inc. ( KOSDAQ:238120 ) shareholders are probably generally happy, the stock hasn't had...

Revenue & Expenses Breakdown

How Aligned Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A238120 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2516,0162,9116,2602,017
30 Sep 2517,3513,7436,1542,465
30 Jun 2517,1733,3175,8672,378
31 Mar 2516,5094,0555,6422,225
31 Dec 2415,7784,1285,6162,292
30 Sep 2414,9992,4785,3642,373
30 Jun 2414,9333,3155,1942,067
31 Mar 2414,9903,4425,1041,722
31 Dec 2315,2153,2365,1251,684
30 Sep 2314,2091,7754,8621,427
30 Jun 2314,0722,1884,7961,352
31 Mar 2313,7642,1134,5391,327
31 Dec 2213,7532,3334,2751,079
30 Sep 2213,8895,3464,444986
30 Jun 2212,8494,1774,219996
31 Mar 2212,9424,6114,037877
31 Dec 2111,7625,5423,794944
30 Sep 2110,3463,9683,378949
30 Jun 2110,0593,3373,331861
31 Mar 218,3221,8553,356924
31 Dec 207,9574683,466816
30 Sep 207,484-1093,501825
30 Jun 207,3591023,931644
31 Mar 207,7383753,691820
31 Dec 197,7941173,629885
30 Sep 197,486-2773,6531,026
30 Jun 196,799-8643,4271,252
31 Mar 196,425-1,0143,7621,083
31 Dec 185,675-1,5883,8831,156
30 Sep 185,385-2,0984,0491,034
30 Jun 185,600-1,8014,0521,017
31 Mar 185,630-1,8813,9591,208
31 Dec 175,636-1,7544,009940
30 Sep 175,487-1,2023,830801
30 Jun 175,085-1,6893,866593
31 Mar 174,806-1,5263,626465
31 Dec 164,712-1,5563,392578
30 Sep 164,407-1,3862,992600
30 Jun 164,249-8332,524715
31 Mar 164,150-7402,588612
31 Dec 154,096-2612,341587

Quality Earnings: A238120 has a high level of non-cash earnings.

Growing Profit Margin: A238120's current net profit margins (18.2%) are lower than last year (26.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A238120's earnings have grown by 2.4% per year over the past 5 years.

Accelerating Growth: A238120's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A238120 had negative earnings growth (-29.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-29.5%).

Return on Equity

High ROE: A238120's Return on Equity (7.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 18:16
End of Day Share Price 2026/05/26 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aligned Genetics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.